Efficacy of Office Fulguration for Recurrent Low Grade Papillary Bladder Tumors Less Than 0.5 cm

Donat, S. Machele; North, Amanda; Dalbagni, Guido; Herr, Harry W.

doi:10.1097/01.ju.0000103100.22951.5e

Cited by 79 publications

(45 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3] Individualized management for each patient, predicting the risk of recurrence and progression in NIMBC is a crucial point. For example, fulguration, [4] adjuvant chemotherapy, [5] or active surveillance alone [6] could be adequate treatment modalities for patients with low potential of recurrence and progression. Controlled, prospective, randomized multicenter studies are required for the selection of appropriate treatment modality.…”

Section: Discussionmentioning

confidence: 99%

Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients

Kılınç¹,

Bayar²,

Dalkılıç³

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: To evaluate the consistency of the results of patients who were treated for non-muscle-invasive bladder cancer (NMIBC) in our clinic with the European Organization for Research and Treatment of Cancer (EORTC) risk table.Material and methods: Data were retrospectively analyzed from 452 patients who had undergone transurethral resection of bladder tumor (TUR-BT) between the years 2002, and 2010 for primary or recurrent NMIBC. Our study had a retrospective design but based on prospective cohort study. Patients were staged according to the 2002 Tumor Node Metastasis (TNM) classification and the 1973 World Health Organization grading system. Recurrence was defined as non-muscle-invasive or muscle-invasive and progression as muscle-invasive tumor determined based on following cystoscopy and TUR-BT results, and confirmed by histopathologic analysis. Patients in the current study were classified into four groups according to the EORTC risk tables. Time to first recurrence and progression was determined for each risk group. Results:Of the 452 patients, 348 were enrolled in this study. The overall mean follow-up period was 55.25 months of all patients. Of 348 patients, 130 (37.4%) and 258 patients (74.1%) had recurrence after treatment at the 1 and 5 year follow-up period, respectively. While 35 (10.1%) and 99 patients (28.4%) progressed to muscle-invasive cancer at the 1 and 5 year follow-up period, respectively. In the multivariate analysis, grade, number, size of the tumor size, and concomitant carcinoma in situ were found to be statistically significant for disease progression and recurrence. Conclusion:When EORTC risk tables were comparatively evaluated in our patient population, we can say that EORTC tables predict nearly accurately the clinical course of patients with NMIBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients

Kılınç¹,

Bayar²,

Dalkılıç³

et al. 2017

Turkish Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Evidence suggests that patients with small papillary tumours who have only had TaLG previously can safely undergo office fulguration. 107 It should be recognized that there are many definitions in the literature for BCG failures: BCG-refractory, BCGintolerant, and BCG relapse. For the purposes of this discussion, we have elected to use the following definitions:…”

Section: Salvage Therapy In Nmibcmentioning

confidence: 99%

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015

Kassouf

Aprikian

Black

et al. 2016

CUAJ

View full text Add to dashboard Cite

This initiative was undertaken in response to concerns regarding the variation in management and in outcomes of patients with bladder cancer throughout centres and geographical areas in Canada. Population-based data have also revealed that real-life survival is lower than expected based on data from clinical trials and/or academic centres. To address these perceived shortcomings and attempt to streamline and unify treatment approaches to bladder cancer in Canada, a multidisciplinary panel of expert clinicians was convened last fall for a two-day working group consensus meeting. The panelists included urologic oncologists, medical oncologists, radiation oncologists, patient representatives, a genitourinary pathologist, and an enterostomal therapy nurse. The following recommendations and summaries of supporting evidence represent the results of the presentations, debates, and discussions. Methodology

show abstract

“…This would reduce the need for OR-based interventions, thus lowering the cost burden of disease, without compromising oncologic outcomes. 6,7 In this study, we sought to quantify and analyze the cost-effectiveness of office-based vs OR-based management of low-risk papillary NMIBC.…”

Section: Resultsmentioning

confidence: 99%

A Cost-effectiveness Analysis of Management of Low-risk Non–muscle-invasive Bladder Cancer Using Office-based Fulguration

Lee

Chughtai

Donat

et al. 2015

Urology

Self Cite

View full text Add to dashboard Cite

Efficacy of Office Fulguration for Recurrent Low Grade Papillary Bladder Tumors Less Than 0.5 cm

Abstract: Office cystodiathermy of small, low grade papillary recurrence is safe and efficacious in properly selected patients. This change in practice can potentially improve patient quality of life and have a major economic impact on health care.

Cited by 79 publications

References 19 publications

Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients

Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015

A Cost-effectiveness Analysis of Management of Low-risk Non–muscle-invasive Bladder Cancer Using Office-based Fulguration

Contact Info

Product

Resources

About